AMP-activated protein kinase: A cellular energy sensor with a key role in metabolic disorders and in cancer

Biochemical Society Transactions

Volumn 39, Issue 1, 2011, Pages 1-13

  Hardie, D Grahame ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

AMP activated protein kinase (AMPK); Cancer; Cell metabolism; Energy balance; Mitochondrion; Type 2 diabetes

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; GLYCOGEN PHOSPHORYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; NUTRACEUTICAL;

ALPHA CHAIN; ANTINEOPLASTIC ACTIVITY; BETA CHAIN; CARBON SOURCE; CELL ENERGY; CELL METABOLISM; CONFERENCE PAPER; DIABETES MELLITUS; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; METABOLIC DISORDER; METABOLIC STRESS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVERNUTRITION; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AWARDS AND PRIZES; CYTOKINES; ENERGY METABOLISM; ENZYME ACTIVATION; HUMANS; METABOLIC DISEASES; NEOPLASMS; PHOSPHORYLATION; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EUKARYOTA;

EID: 79551487613     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0390001     Document Type: Conference Paper

References (146)

1. Konrad, M. (1993) Molecular analysis of the essential gene for adenylate kinase from the fission yeast Schizosaccharomyces pombe. J. Biol. Chem. 268, 11326-11334
2. Hardie, D.G. and Hawley, S.A. (2001) AMP-activated protein kinase: the energy charge hypothesis revisited. BioEssays 23, 1112-1119
3. Cori, G.T., Colowick, S.P. and Cori, C.F. (1938) The action of nucleotides in the disruptive phosphorylation of glycogen. J. Biol. Chem. 123, 381-389
4. Mansour, T.E. (1963) Studies on heart phosphofructokinase: purification, inhibition and activation. J. Biol. Chem. 238, 2285-2292
5. Ramaiah, A., Hathaway, J.A. and Atkinson, D.E. (1964) Adenylate as a metabolic regulator: effect on yeast phosphofructokinase kinetics. J. Biol. Chem. 239, 3619-3622
6. Atkinson, D.E. (1977) Cellular Energy Metabolism and its Regulation. Academic Press, New York
7. Marsin, A.S., Bertrand, L., Rider, M.H., Deprez, J., Beauloye, C., Vincent, M.F., Van Den Berghe, G., Carling, D. and Hue, L. (2000) Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 10, 1247-1255
8. Marsin, A.S., Bouzin, C., Bertrand, L. and Hue, L. (2002) The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J. Biol. Chem. 277, 30778-30783
9. Carlson, C.A. and Kim, K.H. (1973) Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J. Biol. Chem. 248, 378-380
10. Beg, Z.H., Allmann, D.W. and Gibson, D.M. (1973) Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and with protein fractions of rat liver cytosol. Biochem. Biophys. Res. Commun. 54, 1362-1369
11. Yeh, L.A., Lee, K.H. and Kim, K.H. (1980) Regulation of rat liver acetyl-CoA carboxylase: regulation of phosphorylation and inactivation of acetyl-CoA carboxylase by the adenylate energy charge. J. Biol. Chem. 255, 2308-2314
12. Ingebritsen, T.S., Lee, H., Parker, R.A. and Gibson, D.M. (1978) Reversible modulation of the activities of both liver microsomal hydroxymethylglutaryl coenzyme A reductase and its inactivating enzyme: evidence for regulation by phosphorylation-dephosphorylation. Biochem. Biophys. Res. Commun. 81, 1268-1277
13. Ferrer, A., Caelles, C., Massot, N. and Hegardt, F.G. (1985) Activation of rat liver cytosolic 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase by adenosine 5′-monophosphate. Biochem. Biophys. Res. Commun. 132, 497-504
14. Carling, D., Zammit, V.A. and Hardie, D.G. (1987) A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 223, 217-222
15. Sim, A.T.R. and Hardie, D.G. (1988) The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase. FEBS Lett. 233, 294-298
16. Clarke, P.R. and Hardie, D.G. (1990) Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J. 9, 2439-2446
17. Hardie, D.G., Carling, D. and Sim, A.T.R. (1989) The AMP-activated protein kinase: a multisubstrate regulator of lipid metabolism. Trends Biochem. Sci. 14, 20-23
18. Hardie, D.G. (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8, 774-785
19. Woods, A., Munday, M.R., Scott, J., Yang, X., Carlson, M. and Carling, D. (1994) Yeast SNF1 is functionally related to mammalian AMP-activated protein kinase and regulates acetyl-CoA carboxylase in vivo. J. Biol. Chem. 269, 19509-19515
20. Chen, L., Jiao, Z.H., Zheng, L.S., Zhang, Y.Y., Xie, S.T., Wang, Z.X. and Wu, J.W. (2009) Structural insight into the autoinhibition mechanism of AMP-activated protein kinase. Nature 459, 1146-1149
21. Xiao, B., Heath, R., Saiu, P., Leiper, F.C., Leone, P., Jing, C., Walker, P.A., Haire, L., Eccleston, J.F., Davis, C.T. et al. (2007) Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 449, 496-500
22. Hawley, S.A., Davison, M., Woods, A., Davies, S.P., Beri, R.K., Carling, D. and Hardie, D.G. (1996) Characterization of the AMP-activated protein kinase kinase from rat liver, and identification of threonine-172 as the major site at which it phosphorylates and activates AMP-activated protein kinase. J. Biol. Chem. 271, 27879-27887
23. Johnson, L.N., Noble, M.E.M. and Owen, D.J. (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85, 149-158
24. Weekes, J., Hawley, S.A., Corton, J., Shugar, D. and Hardie, D.G. (1994) Activation of rat liver AMP-activated protein kinase by the upstream kinase kinase in a purified, reconstituted system: effects of AMP and AMP analogues. Eur. J. Biochem. 219, 751-757
25. C. FEBS Lett. 377, 421-425
26. Sanders, M.J., Grondin, P.O., Hegarty, B.D., Snowden, M.A. and Carling, D. (2007) Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J. 403, 139-148
27. Hudson, E.R., Pan, D.A., James, J., Lucocq, J.M., Hawley, S.A., Green, K.A., Baba, O., Terashima, T. and Hardie, D.G. (2003) A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr. Biol. 13, 861-866
28. Polekhina, G., Gupta, A., Michell, B.J., van Denderen, B., Murthy, S., Feil, S.C., Jennings, I.G., Campbell, D.J., Witters, L.A., Parker, M.W. et al. (2003) AMPK β-subunit targets metabolic stress-sensing to glycogen. Curr. Biol. 13, 867-871
29. Polekhina, G., Gupta, A., van Denderen, B.J., Feil, S.C., Kemp, B.E., Stapleton, D. and Parker, M.W. (2005) Structural basis for glycogen recognition by AMP-activated protein kinase. Structure 13, 1453-1462 (Pubitemid 41427585)
30. Bendayan, M., Londono, I., Kemp, B.E., Hardie, G.D., Ruderman, N. and Prentki, M. (2009) Association of AMP-activated protein kinase subunits with glycogen particles as revealed in situ by immunoelectron microscopy. J. Histochem. Cytochem. 57, 963-971
31. McBride, A., Ghilagaber, S., Nikolaev, A. and Hardie, D.G. (2009) The glycogen-binding domain on AMP-activated protein kinase is a regulatory domain that allows the kinase to act as a sensor of glycogen structure. Cell Metab. 9, 23-34
32. Kemp, B.E. (2004) Bateman domains and adenosine derivatives form a binding contract. J. Clin. Invest. 113, 182-184
33. Bateman, A. (1997) The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem. Sci. 22, 12-13
34. Scott, J.W., Hawley, S.A., Green, K.A., Anis, M., Stewart, G., Scullion, G.A., Norman, D.G. and Hardie, D.G. (2004) CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J. Clin. Invest. 113, 274-284
35. Katinka, M.D., Duprat, S., Cornillot, E., Metenier, G., Thomarat, F., Prensier, G., Barbe, V., Peyretaillade, E., Brottier, P., Wincker, P. et al. (2001) Genome sequence and gene compaction of the eukaryote parasite Encephalitozoon cuniculi. Nature 414, 450-453
36. Hardie, D.G., Carling, D. and Carlson, M. (1998) The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem. 67, 821-855
37. Apfeld, J., O'Connor, G., McDonagh, T., Distefano, P.S. and Curtis, R. (2004) The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in C. elegans. Genes Dev. 18, 3004-3009 (Pubitemid 39658169)
38. Narbonne, P. and Roy, R. (2006) Inhibition of germline proliferation during C. elegans dauer development requires PTEN, LKB1 and AMPK signalling. Development 133, 611-619
39. Thelander, M., Olsson, T. and Ronne, H. (2004) Snf1-related protein kinase 1 is needed for growth in a normal day-night light cycle. EMBO J. 23, 1900-1910 (Pubitemid 38649652)
40. Polge, C. and Thomas, M. (2007) SNF1/AMPK/SnRK1 kinases, global regulators at the heart of energy control? Trends Plant Sci. 12, 20-28
41. 2+/calmodulin the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J. Biol. Chem. 270, 27186-27191
42. Nath, N., McCartney, R.R. and Schmidt, M.C. (2003) Yeast Pak1 kinase associates with and activates Snf1. Mol. Cell. Biol. 23, 3909-3917
43. Sutherland, C.M., Hawley, S.A., McCartney, R.R., Leech, A., Stark, M.J., Schmidt, M.C. and Hardie, D.G. (2003) Elm1p is one of three upstream kinases for the Saccharomyces cerevisiae SNF1 complex. Curr. Biol. 13, 1299-1305
44. Hong, S.P., Leiper, F.C., Woods, A., Carling, D. and Carlson, M. (2003) Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl. Acad. Sci. U.S.A. 100, 8839-8843
45. Hawley, S.A., Boudeau, J., Reid, J.L., Mustard, K.J., Udd, L., Makela, T.P., Alessi, D.R. and Hardie, D.G. (2003) Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28
46. Alessi, D.R., Sakamoto, K. and Bayascas, J.R. (2006) Lkb1-dependent signaling pathways. Annu. Rev. Biochem. 75, 137-163
47. Wingo, S.N., Gallardo, T.D., Akbay, E.A., Liang, M.C., Contreras, C.M., Boren, T., Shimamura, T., Miller, D.S., Sharpless, N.E., Bardeesy, N. et al. (2009) Somatic LKB1 mutations promote cervical cancer progression. PLoS ONE 4, e5137
48. Woods, A., Johnstone, S.R., Dickerson, K., Leiper, F.C., Fryer, L.G., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M. and Carling, D. (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13, 2004-2008
49. Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kosmatka, M., DePinho, R.A. and Cantley, L.C. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99
50. Hawley, S.A., Pan, D.A., Mustard, K.J., Ross, L., Bain, J., Edelman, A.M., Frenguelli, B.G. and Hardie, D.G. (2005) Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2, 9-19
51. 2+/calmodulin- dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2, 21-33
52. 2+/calmoldulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 280, 29060-29066
53. 2+ and AMP. Biochem. J. 426, 109-118
54. 2+ in T lymphocytes. J. Exp. Med. 203, 1665-1670
55. 2+/calmodulin-dependent protein kinase kinase β. Mol. Cell. Biol. 26, 5933-5945
56. Momcilovic, M., Hong, S.P. and Carlson, M. (2006) Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 281, 25336-25343
57. Herrero-Martin, G., Hoyer-Hansen, M., Garcia-Garcia, C., Fumarola, C., Farkas, T., Lopez-Rivas, A. and Jaattela, M. (2009) TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 28, 677-685
58. Merrill, G.M., Kurth, E., Hardie, D.G. and Winder, W.W. (1997) AICAR decreases malonyl-CoA and increases fatty acid oxidation in skeletal muscle of the rat. Am. J. Physiol. 273, E1107-E1112
59. Kurth-Kraczek, E.J., Hirshman, M.F., Goodyear, L.J. and Winder, W.W. (1999) 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48, 1667-1671
60. Barnes, K., Ingram, J.C., Porras, O.H., Barros, L.F., Hudson, E.R., Fryer, L.G., Foufelle, F., Carling, D., Hardie, D.G. and Baldwin, S.A. (2002) Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J. Cell Sci. 115, 2433-2442
61. Zheng, D., MacLean, P.S., Pohnert, S.C., Knight, J.B., Olson, A.L., Winder, W.W. and Dohm, G.L. (2001) Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J. Appl. Physiol. 91, 1073-1083
62. Zong, H., Ren, J.M., Young, L.H., Pypaert, M., Mu, J., Birnbaum, M.J. and Shulman, G.I. (2002) AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. U.S.A. 99, 15983-15987
63. Jager, S., Handschin, C., St-Pierre, J. and Spiegelman, B.M. (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proc. Natl. Acad. Sci. U.S.A. 104, 12017-12022
64. + metabolism and SIRT1 activity. Nature 458, 1056-1060
65. Inoki, K., Zhu, T. and Guan, K.L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590 (Pubitemid 37506046)
66. Gwinn, D.M., Shackelford, D.B., Egan, D.F., Mihaylova, M.M., Mery, A., Vasquez, D.S., Turk, B.E. and Shaw, R.J. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214-226
67. Winder, W.W. and Hardie, D.G. (1996) Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol. 270, E299-E304
68. Corton, J.M., Gillespie, J.G. and Hardie, D.G. (1994) Role of the AMP-activated protein kinase in the cellular stress response. Curr. Biol. 4, 315-324
69. Salt, I.P., Johnson, G., Ashcroft, S.J. H. and Hardie, D.G. (1998) AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic β cells, and may regulate insulin release. Biochem. J. 335, 533-539
70. Kudo, N., Barr, A.J., Barr, R.L., Desai, S. and Lopaschuk, G.D. (1995) High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J. Biol. Chem. 270, 17513-17520
71. Sakamoto, K., McCarthy, A., Smith, D., Green, K.A., Hardie, D.G., Ashworth, A. and Alessi, D.R. (2005) Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 24, 1810-1820
72. Hardie, D.G. and Sakamoto, K. (2006) AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology 21, 48-60
73. Claret, M., Smith, M.A., Batterham, R.L., Selman, C., Choudhury, A.I., Fryer, L.G., Clements, M., Al-Qassab, H., Heffron, H., Xu, A.W. et al. (2007) AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J. Clin. Invest. 117, 2325-2336
74. Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y.B., Lee, A., Xue, B., Mu, J., Foufelle, F., Ferré, P., Birnbaum, M.J. et al. (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428, 569-574
75. Andersson, U., Filipsson, K., Abbott, C.R., Woods, A., Smith, K., Bloom, S.R., Carling, D. and Small, C.J. (2004) AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279, 12005-12008
76. McCrimmon, R.J., Shaw, M., Fan, X., Cheng, H., Ding, Y., Vella, M.C., Zhou, L., McNay, E.C. and Sherwin, R.S. (2008) Key role for AMP-activated protein kinase in the ventromedial hypothalamus in regulating counterregulatory hormone responses to acute hypoglycemia. Diabetes 57, 444-450
77. Evans, A.M., Mustard, K.J., Wyatt, C.N., Peers, C., Dipp, M., Kumar, P., Kinnear, N.P. and Hardie, D.G. (2005) Does AMP-activated protein kinase couple inhibition of mitochondrial oxidative phosphorylation by hypoxia to calcium signaling in O2-sensing cells? J. Biol. Chem. 280, 41504-41511
78. Evans, A.M., Hardie, D.G., Peers, C., Wyatt, C.N., Viollet, B., Kumar, P., Dallas, M.L., Ross, F., Ikematsu, N., Jordan, H.L. et al. (2009) Ion channel regulation by AMPK: the route of hypoxia-response coupling in thecarotid body and pulmonary artery. Ann. N.Y. Acad. Sci. 1177, 89-100
79. Robertson, T.P., Mustard, K.J., Lewis, T.H., Clark, J.H., Wyatt, C.N., Blanco, E.A., Peers, C., Hardie, D.G. and Evans, A.M. (2008) AMP-activated protein kinase and hypoxic pulmonary vasoconstriction. Eur. J. Pharmacol. 595, 39-43
80. Wyatt, C.N., Mustard, K.J., Pearson, S.A., Dallas, M.L., Atkinson, L., Kumar, P., Peers, C., Hardie, D.G. and Evans, A.M. (2007) AMP-activated protein kinase mediates carotid body excitation by hypoxia. J. Biol. Chem. 282, 8092-8098
81. Minokoshi, Y., Kim, Y.B., Peroni, O.D., Fryer, L.G., Muller, C., Carling, D. and Kahn, B.B. (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415, 339-343
82. Kola, B., Hubina, E., Tucci, S.A., Kirkham, T.C., Garcia, E.A., Mitchell, S.E., Williams, L.M., Hawley, S.A., Hardie, D.G., Grossman, A.B. and Korbonits, M. (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J. Biol. Chem. 280, 25196-25201
83. Kubota, N., Yano, W., Kubota, T., Yamauchi, T., Itoh, S., Kumagai, H., Kozono, H., Takamoto, I., Okamoto, S., Shiuchi, T. et al. (2007) Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 6, 55-68
84. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K. et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79-83
85. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K. et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 6, 1288-1295
86. Kadowaki, T. and Yamauchi, T. (2005) Adiponectin and adiponectin receptors. Endocr. Rev. 26, 439-451
87. Carey, A.L., Steinberg, G.R., Macaulay, S.L., Thomas, W.G., Holmes, A.G., Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M.J., James, D.E. et al. (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55, 2688-2697
88. Steinberg, G.R., Watt, M.J., Fam, B.C., Proietto, J., Andrikopoulos, S., Allen, A.M., Febbraio, M.A. and Kemp, B.E. (2006) Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology 147, 3906-3914 (Pubitemid 44079396)
89. Watt, M.J., Dzamko, N., Thomas, W.G., Rose-John, S., Ernst, M., Carling, D., Kemp, B.E., Febbraio, M.A. and Steinberg, G.R. (2006) CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat. Med. 12, 541-548
90. Miller, E.J., Li, J., Leng, L., McDonald, C., Atsumi, T., Bucala, R. and Young, L.H. (2008) Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451, 578-582 (Pubitemid 351186266)
91. Kim, M.S., Park, J.Y., Namkoong, C., Jang, P.G., Ryu, J.W., Song, H.S., Yun, J.Y., Namgoong, I.S., Ha, J., Park, I.S. et al. (2004) Anti-obesity effects of α-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med. 10, 727-733
92. Winder, W.W. and Hardie, D.G. (1999) The AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes. Am. J. Physiol. 277, E1-E10
93. Corton, J.M., Gillespie, J.G., Hawley, S.A. and Hardie, D.G. (1995) 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558-565
94. Song, X.M., Fiedler, M., Galuska, D., Ryder, J.W., Fernström, M., Chibalin, A.V., Wallberg-Henriksson, H. and Zierath, J.R. (2002) 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (oblob) mice. Diabetologia 45, 56-65
95. Buhl, E.S., Jessen, N., Schmitz, O., Pedersen, S.B., Pedersen, O., Holman, G.D. and Lund, S. (2001) Chronic treatment with 5-aminoimidazole-4- carboxamide-1-β-d-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes 50, 12-17
96. Bergeron, R., Previs, S.F., Cline, G.W., Perret, P., Russell, R.R., 3rd, Young, L.H. and Shulman, G.I. (2001) Effect of 5-aminoimidazole-4-carboxamide-1- β-d-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 50, 1076-1082
97. Iglesias, M.A., Ye, J.M., Frangioudakis, G., Saha, A.K., Tomas, E., Ruderman, N.B., Cooney, G.J. and Kraegen, E.W. (2002) AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 51, 2886-2894
98. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N. et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174
99. Fryer, L.G., Parbu-Patel, A. and Carling, D. (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct pathways. J. Biol. Chem. 277, 25226-25232
100. Hawley, S.A., Gadalla, A.E., Olsen, G.S. and Hardie, D.G. (2002) The anti-diabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51, 2420-2425
101. Shaw, R.J., Lamia, K.A., Vasquez, D., Koo, S.H., Bardeesy, N., Depinho, R.A., Montminy, M. and Cantley, L.C. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646 (Pubitemid 41780780)
102. Saha, A.K., Avilucea, P.R., Ye, J.M., Assifi, M.M., Kraegen, E.W. and Ruderman, N.B. (2004) Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem. Biophys. Res. Commun. 314, 580-585
103. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M. and Kliewer, S.A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ ). J. Biol. Chem. 270, 12953-12956
104. Kubota, N., Terauchi, Y., Kubota, T., Kumagai, H., Itoh, S., Satoh, H., Yano, W., Ogata, H., Tokuyama, K., Takamoto, I. et al. (2006) Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J. Biol. Chem. 281, 8748-8755
105. Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K. et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342
106. Hwang, J.T., Park, I.J., Shin, J.I., Lee, Y.K., Lee, S.K., Baik, H.W., Ha, J. and Park, O.J. (2005) Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 338, 694-699
107. Ahn, J., Lee, H., Kim, S., Park, J. and Ha, T. (2008) The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem. Biophys. Res. Commun. 373, 545-549
108. Lee, Y.S., Kim, W.S., Kim, K.H., Yoon, M.J., Cho, H.J., Shen, Y., Ye, J.M., Lee, C.H., Oh, W.K., Kim, C.T. et al. (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55, 2256-2264
109. Owen, M.R., Doran, E. and Halestrap, A.P. (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607-614
110. El-Mir, M.Y., Nogueira, V., Fontaine, E., Averet, N., Rigoulet, M. and Leverve, X. (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223-228
111. Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Gnaiger, E., Nohl, H., Waldhausl, W. and Furnsinn, C. (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53, 1052-1059
112. Turner, N., Li, J.Y., Gosby, A., To, S.W., Cheng, Z., Miyoshi, H., Taketo, M.M., Cooney, G.J., Kraegen, E.W., James, D.E. et al. (2008) Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57, 1414-1418
113. Gledhill, J.R., Montgomery, M.G., Leslie, A.G. and Walker, J.E. (2007) Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. U.S.A. 104, 13632-13637
114. Hawley, S.A., Ross, F.A., Chevtzoff, C., Green, K.A., Evans, A., Fogarty, S., Towler, M.C., Brown, L.J., Ogunbayo, O.A., Evans, A.M. and Hardie, D.G. (2010) Use of cells expressing γ subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 11, 554-565
115. Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., Dickinson, R., Adler, A., Gagne, G., Iyengar, R. et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of Type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403-416
116. Goransson, O., McBride, A., Hawley, S.A., Ross, F.A., Shpiro, N., Foretz, M., Viollet, B., Hardie, D.G. and Sakamoto, K. (2007) Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 282, 32549-32560
117. Sanders, M.J., Ali, Z.S., Hegarty, B.D., Heath, R., Snowden, M.A. and Carling, D. (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 282, 32539-32548
118. Mooney, M.H., Fogarty, S., Stevenson, C., Gallagher, A.M., Palit, P., Hawley, S.A., Hardie, D.G., Coxon, G.D., Waigh, R.D., Tate, R.J. et al. (2008) Mechanisms underlying the metabolic actions of galegine that contribute to weight loss in mice. Br. J. Pharmacol. 153, 1669-1677
119. Romero-Perez, A.I., Lamuela-Raventos, R.M., Andres-Lacueva, C. and de La Torre-Boronat, M.C. (2001) Method for the quantitative extraction of resveratrol and piceid isomers in grape berry skins: effect of powdery mildew on the stilbene content. J. Agric. Food Chem. 49, 210-215
120. Lizcano, J.M., Göransson, O., Toth, R., Deak, M., Morrice, N.A., Boudeau, J., Hawley, S.A., Udd, L., Mäkelä, T.P., Hardie, D.G. and Alessi, D.R. (2004) LKB1 is a master kinase that activates 13 protein kinases of the AMPK subfamily, including the MARK/PAR-1 kinases. EMBO J. 23, 833-843
121. Imamura, K., Ogura, T., Kishimoto, A., Kaminishi, M. and Esumi, H. (2001) Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-β-d- ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 287, 562-567
122. Warburg, O. (1926) Über die airkung von blausäureä thylester (äthylcarbylamin) auf die Pasteursche reaktion. Biochem. Z. 172, 432-441
123. Winder, W.W., Holmes, B.F., Rubink, D.S., Jensen, E.B., Chen, M. and Holloszy, J.O. (2000) Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J. Appl. Physiol. 88, 2219-2226
124. Pollard, P.J., Briere, J.J., Alam, N.A., Barwell, J., Barclay, E., Wortham, N.C., Hunt, T., Mitchell, M., Olpin, S., Moat, S.J. et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239
125. Thomas, G.V., Tran, C., Mellinghoff, I.K., Welsbie, D.S., Chan, E., Fueger, B., Czernin, J. and Sawyers, C.L. (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12, 122-127
126. Bowker, S.L., Majumdar, S.R., Veugelers, P. and Johnson, J.A. (2006) Increased cancer-related mortality for patients with Type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254-258 (Pubitemid 44106500)
127. Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R. and Morris, A.D. (2005) Metformin and reduced risk of cancer in diabetic patients. Br. Med. J. 330, 1304-1305
128. Ogunleye, A.A., Ogston, S.A., Morris, A.D. and Evans, J.M. (2009) A cohort study of the risk of cancer associated with Type 2 diabetes. Br. J. Cancer 101, 1199-1201
129. Currie, C.J., Poole, C.D. and Gale, E.A. (2009) The influence of glucose-lowering therapies on cancer risk in Type 2 diabetes. Diabetologia 52, 1766-1777
130. Monami, M., Lamanna, C., Balzi, D., Marchionni, N. and Mannucci, E. (2009) Sulphonylureas and cancer: a case-control study. Acta Diabetol. 46, 279-284
131. Donadon, V., Balbi, M., Ghersetti, M., Grazioli, S., Perciaccante, A., Della Valentina, G., Gardenal, R., Dal Mas, M., Casarin, P., Zanette, G. and Miranda, C. (2009) Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol. 15, 2506-2511
132. Li, D., Yeung, S.C., Hassan, M.M., Konopleva, M. and Abbruzzese, J.L. (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137, 482-488
133. Wright, J.L. and Stanford, J.L. (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20, 1617-1622
134. Jiralerspong, S., Palla, S.L., Giordano, S.H., Meric-Bernstam, F., Liedtke, C., Barnett, C.M., Hsu, L., Hung, M.C., Hortobagyi, G.N. and Gonzalez-Angulo, A.M. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27, 3297-3302
135. Anisimov, V.N., Berstein, L.M., Egormin, P.A., Piskunova, T.S., Popovich, I.G., Zabezhinski, M.A., Kovalenko, I.G., Poroshina, T.E., Semenchenko, A.V., Provinciali, M. et al. (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol. 40, 685-693
136. Huang, X., Wullschleger, S., Shpiro, N., McGuire, V.A., Sakamoto, K., Woods, Y.L., McBurnie, W., Fleming, S. and Alessi, D.R. (2008) Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 412, 211-221
137. Hadad, S.M., Baker, L., Quinlan, P.R., Robertson, K.E., Bray, S.E., Thomson, G., Kellock, D., Jordan, L.B., Purdie, C.A., Hardie, D.G. et al. (2009) Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 9, 307
138. Sanchez-Cespedes, M., Parrella, P., Esteller, M., Nomoto, S., Trink, B., Engles, J.M., Westra, W.H., Herman, J.G. and Sidransky, D. (2002) Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62, 3659-3662
139. Ji, H., Ramsey, M.R., Hayes, D.N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M.C., Shimamura, T., Perera, S.A. et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810
140. Gurumurthy, S., Hezel, A.F., Sahin, E., Berger, J.H., Bosenberg, M.W. and Bardeesy, N. (2008) LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res. 68, 55-63
141. Pearson, H.B., McCarthy, A., Collins, C.M., Ashworth, A. and Clarke, A.R. (2008) Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res. 68, 2223-2232
142. Contreras, C.M., Akbay, E.A., Gallardo, T.D., Haynie, J.M., Sharma, S., Tagao, O., Bardeesy, N., Takahashi, M., Settleman, J., Wong, K.K. and Castrillon, D.H. (2010) Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis. Models Mech. 3, 181-193
143. Skloot, R. (2010) The Immortal Life of Henrietta Lacks, Macmillan, London
144. Zheng, B., Jeong, J.H., Asara, J.M., Yuan, Y.Y., Granter, S.R., Chin, L. and Cantley, L.C. (2009) Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 33, 237-247
145. 485/491. J. Biol. Chem. 281, 5335-5340
146. Mankouri, J., Tedbury, P.R., Gretton, S., Hughes, M.E., Griffin, S.D., Dallas, M.L., Green, K.A., Hardie, D.G., Peers, C. and Harris, M. (2010) Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc. Natl. Acad. Sci. U.S.A. 107, 11549-11554